Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Adoptive cell transfer (ACT) using chimeric antigen receptor (CAR)‐modified T cells can
induce durable remissions in patients with refractory B‐lymphoid cancers. By contrast …

T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a
minority of patients with cancer. In the majority of these individuals, however, there is a …

In recent years, various nanotechnology platforms in the area of medical biology, including
both diagnostics and therapy, have gained remarkable attention. Moreover, research and …

Cytotoxic chemotherapy or radiotherapy of cancer is limited by serious, sometimes life-
threatening, side effects that arise from toxicities to sensitive normal cells because the …

Antibody-based sensors permit the rapid and sensitive analysis of a range of pathogens and
associated toxins. A critical assessment of the implementation of such formats is provided …

2004-11-10 Assigned to XENCOR, INC. reassignment XENCOR, INC. ASSIGNMENT OF
ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DANG, WEI …

The majority of clinically approved anticancer drugs are characterized by a narrow
therapeutic window that results mainly from a high systemic toxicity of the drugs in …

Nanotechnology is a field of research at the crossroads of biology, chemistry, physics,
engineering, and medicine. Design of multifunctional nanoparticles capable of targeting …

The discovery of hybridoma technology, described by Kohler and Milstein in 1975, and the
resulting ability to generate monoclonal antibodies (mAbs) initiated a new era in antibody …